AstraZeneca said on Monday its experimental weight-loss pill, licensed from China's Eccogene, was safe and tolerable in an ...

Researchers from the University of Copenhagen have discovered a new weight loss drug target that works without causing nausea ...

AstraZeneca Plc said its experimental obesity pill was well-tolerated by patients with type-2 diabetes as it presented data from several studies testing its three new weight-loss medicines.

Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...

In its presentation at ObesityWeek 2024 meeting in Texas, the multinational drug company AstraZeneca (NASDAQ:AZN) revealed ...

The catalyst in relation to this program is not that far off, because top-line data from this phase 2b IMPACT study using ...

A new weight loss drug target may help reduce appetite and burn calories without causing sickness, research suggests. The ...

The Anglo-Swedish drugmaker’s closely watched weight loss pill, AZD5004, showed 5.8% weight loss after four weeks of treatment among patients with type 2 diabetes, it said Monday during the ...

Jefferies analyst Roger Song in an investor note said that Viking Therapeutics’ readout for its investigational therapy ...

Altimmune, Inc.’s Pemvidutide shows promise as a dual-action treatment for obesity and MASLD/MASH ... stock to a “Strong Buy” ...

Researchers at the University of Copenhagen have identified a promising new drug target for weight loss which could revolutionise treatment for millions of people with obesity and type 2 diabetes. The ...